Improved Retroviruses for Gene Therapy

Back to all technologies
Download as PDF
61136
Transducing cells with viral vectors to deliver novel nucleic acids requires a specific ligand or envelope glycoprotein on the virus surface to bind to a receptor on a target cell. By changing the ligand on the virus (pseudotyping), it is possible to enhance the transduction efficiency towards target cell types. For this technology, Ebola glycoprotein-pseudotyped retroviruses were produced for gene transduction into the lung and other tissues and for the study of Ebola virus entry into cells.

Researchers at Purdue University have developed a technology that allows quantitative measurement of virus entry into host cells and determination of the effectiveness of reagents that inhibit entry. This technology also allows for the production of Ebola glycoprotein-pseudotyped retroviruses with markedly improved titers, making the practical use of such viruses more feasible.

Advantages:
- Allows gene therapy of the lung using pseudotyped retroviruses
- Improved safety and efficiency

Potential Applications:
-Medical/Healthcare
-Pharmaceuticals
-Drug Development
-Antivirals
-Gene/Cell Therapy
Dec 2, 2004
Utility Patent
United States
7,981,656 B2
Jul 19, 2011

Jun 4, 2003
PCT-Patent
WO
(None)
(None)

Mar 27, 2003
Provisional-Patent
United States
(None)
(None)

Jun 4, 2002
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org